Table 1. Baseline Clinical Characteristics of the Study Subjects (n=124).
| Variable | Total | Non-obese group | Obese group | P valuea |
|---|---|---|---|---|
| Number | 124 | 72 | 52 | |
| Age, yr | 59.9±7.1 | 59.6±7.4 | 60.2±6.7 | 0.641 |
| Body mass index, kg/m2 | 24.4±2.8 | 22.4±1.5 | 27.1±2.0 | <0.001 |
| Systolic blood pressure, mm Hg | 123.9±16.0 | 120.2±15.2 | 128.8±16.0 | 0.003 |
| Diastolic blood pressure, mm Hg | 75.8±10.5 | 72.5±9.6 | 80.0±10.3 | <0.001 |
| Age at menopause, yr | 50.8±3.6 | 51.0±3.3 | 50.5±4.0 | 0.455 |
| No. of years since menopause | 9.1±7.6 | 8.7±7.9 | 9.7±7.2 | 0.430 |
| Serum DPP-4 activity, ng/mL | 616.7±127.4 | 623.6±128.3 | 607.1±126.7 | 0.479 |
| Calcium, mg/dL | 9.5±0.3 | 9.5±0.3 | 9.5±0.3 | 0.985 |
| Phosphate, mg/dL | 3.8±0.5 | 3.9±0.5 | 3.8±0.5 | 0.289 |
| Albumin, g/dL | 4.3±0.3 | 4.3±0.3 | 4.3±0.2 | 0.973 |
| Creatinine, mg/dL | 0.6±0.1 | 0.6±0.1 | 0.6±0.1 | 0.835 |
| Osteocalcin, ng/mL | 12.6±2.7 | 12.5±2.5 | 12.7±3.1 | 0.676 |
| C-telopeptide, ng/mL | 0.78±0.36 | 0.80±0.42 | 0.75±0.26 | 0.378 |
| Intact PTH, pg/mL | 0.092±0.050 | 0.098±0.059 | 0.084±0.032 | 0.108 |
| 25-Vitamin D3, ng/mL | 6.1±3.3 | 6.3±3.4 | 5.8±3.2 | 0.440 |
| BMD (g/cm2) by DXA | ||||
| BMD of spine | 0.993±0.150 | 0.950±0.135 | 1.053±0.151 | <0.001 |
| BMD of femoral neck | 0.081±0.107 | 0.786±0.108 | 0.823±0.103 | 0.061 |
| BMD of total hip | 0.886±0.124 | 0.859±0.117 | 0.924±0.124 | 0.003 |
| Total fragility fracture history | ||||
| Total fracture history | 23 (18.5) | 14 (19.4) | 9 (17.3) | 0.099 |
| Spine fracture history | 1 (0.8) | 0 | 1 (1.9) | 0.311 |
| Hip fracture history | 0 | 0 | 0 | 0.159 |
Values are expressed as mean±SD or number (%).
DPP-4, dipeptidyl peptidase 4; PTH, parathyroid hormone; BMD, bone mineral density; DXA, dual-emission X-ray absorptiometry.
aP value was measured between non-obese and obese group.